Research Library

The Commission on Combatting Drug Addiction and the Opioid Crisis appointed by President Trump released its report on Monday, July 31. Drug policy fellow Katharine Neill Harris assesses the commission's recommendations in the Baker Institute Blog.

The 340B Drug Pricing Program, which allows uninsured or low-income patients to buy prescription drugs at discounted prices, is under attack.

In this commentary, the authors examine the roots of the United States’ reluctance to embrace universal health care, concluding that it "is neither sound nor ethical in a nation that promulgates fairness and equal opportunity" to deny coverage.

Asthma in children costs an estimated $27 billion annually for doctor visits, emergency department visits and hospitalizations. Not surprisingly, kids with asthma miss more days of school and do worse academically. The first step to the management and treatment of asthma is access to a primary care provider who can prescribe the necessary medications and develop an asthma action plan. However, if we want to have a significant impact on the negative consequences of this disease on our children, a multi-faceted approach that includes policy is an absolute must.

It is inconceivable to imagine our nation today without the gains of the Civil Rights Act. It is impossible to understand why the issue was so divisive then, since it is such an obvious right and moral proposition. Similarly, let us hope we will look back at the Affordable Care Act 20 years from now and wonder why it was such a contentious topic in 2014.

Baker Institute health policy experts Hagop M. Kantarjian and Vivian Ho explain why Texas, which holds the notorious record of the highest rate of uninsured citizens in the U.S., should follow many Republican-led states that are now reconsidering the Medicaid expansion program under Obamacare.